摘要
目的分析2010-2012年武汉地区32家医院应用抗肿瘤分子靶向治疗药物状况。方法应用金额排序法和用药频度(DDDs)排序法,对武汉市32家医院近三年临床使用的抗肿瘤分子靶向治疗药物进行回顾性统计和分析。结果武汉地区抗肿瘤分子靶向治疗药物销售金额与DDDs逐年稳定增长,日均费用(DDC)相对稳定。各类药品销售金额与DDDs排序趋势一致,国产新药埃克替尼的销售金额及DDDs增长较快。结论 2010-2012年武汉地区应用抗肿瘤分子靶向治疗药物状况符合临床应用特点,销售金额及DDDs排序合理。
Objective To analyse the application of antineoplastic molecular targeted drug in 32 hospitals in Wuhan area during 2010-2012.Methods Applied the amount of sorting and DDDs sorting to count and analyse the situation of an-tineoplastic molecular targeted drug application in 32 hospitals of Wuhan city in recent three years.Results The sales amount and DDDs of antineoplastic molecular targeted drug in the treatment of Wuhan area were increased steadily year by year,DDC was relatively stable.All kinds of the amount of drug sales and DDDs sorted the favorable trend.Sales amount and DDDs of do-mestic new drugs Icotinib were growing faster.Conclusion The application status of antineoplastic molecular targeted drug in Wuhan area during 2010-2012 were conform to the clinical application characteristics,while the sales amount and DDDs were sorted reasonably.
出处
《临床合理用药杂志》
2014年第34期4-5,共2页
Chinese Journal of Clinical Rational Drug Use
